Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study

Liver International

Volumn 35, Issue 9, 2015, Pages 2155-2166

  Park, Joong Won ^a,k   Chen, Minshan ^b   Colombo, Massimo ^c   Roberts, Lewis R ^d   Schwartz, Myron ^e   Chen, Pei Jer ^f   Kudo, Masatoshi ^g   Johnson, Philip ^h   Wagner, Samuel ⁱ   Orsini, Lucinda S ⁱ   Sherman, Morris ^j  

^a National Cancer Center   (South Korea)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c UNIVERSITY OF MILAN   (Italy)

^d MAYO CLINIC   (United States)

^e MOUNT SINAI HOSPITAL   (United States)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k NONE   (South Korea)

more..

Author keywords

Disease management; Epidemiology; Global trends; Liver cancer; Observational study; Risk factors; Treatment patterns

Indexed keywords

SORAFENIB; ALCOHOL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CHEMOEMBOLIZATION; CHINA; COHORT ANALYSIS; CONTROLLED STUDY; EUROPE; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER RESECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NORTH AMERICA; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; RISK FACTOR; SOUTH KOREA; TAIWAN; ARTIFICIAL EMBOLIZATION; ASIA; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CLINICAL TRIAL; COMPLICATION; DISEASE MANAGEMENT; EPIDEMIOLOGY; HEPATITIS B; HEPATITIS C; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; VIROLOGY;

ADULT; AGED; ASIA; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; DISEASE MANAGEMENT; EMBOLIZATION, THERAPEUTIC; ETHANOL; EUROPE; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NORTH AMERICA; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84984564079     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12818     Document Type: Article

References (40)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0. Estimated cancer incidence, mortality, and prevalence worldwide. Available at http://globocan.iarc.fr. Accessed 28 March 2014.
2. European Association for The Study Of The Liver, European Organisation for Research And Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
4. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.
5. El Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
6. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
7. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, Available at http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, 2013. Accessed: 12 March 2015.
8. Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med 2012; 4: 19-37.
9. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
10. Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107: 569-77.
11. Shiina S, Tateishi R, Imamura M, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int 2012; 32: 1434-42.
12. Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc 2006; 98: 1934-9.
13. Carrilho FJ, Kikuchi L, Branco F, Goncalves CS, Mattos AA; Brazilian HCC Study Group. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics (Sao Paulo). 2010; 65: 1285-90.
14. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28: 3994-4005.
15. Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol 2013; 7: 87-102.
16. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
17. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
18. Welker MW, Lubomierski N, Gog C, et al. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemother 2010; 22: 205-11.
19. Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 2010; 15(Suppl 4): 42-52.
20. Park J-W, Sherman M, Colombo M, et al. Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: first characterization of the full study population. Poster 4033. Presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1-5, 2012; Chicago, Illinois.
21. Kudo M, Okanoue T; Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72(Suppl 1): 2-15.
22. Korean Liver Cancer Study Group and National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009; 15: 391-423. [Article in Korean]
23. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
24. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984; 53: 2002-7.
25. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15(Suppl 4): 5-13.
26. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010; 24: 899-919, viii.
27. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(5 Suppl 1): S5-16.
28. Su FH, Huang HY, Chang HJ, et al. Forecasting the declining rate of chronic hepatitis-B carrier status at a Taiwanese university: twenty years after implementation of an universal HBV vaccination program in Taiwan. Chang Gung Med J 2007; 30: 521-8.
29. Ni YH, Chen DS. Hepatitis B vaccination in children: the Taiwan experience. Pathol Biol (Paris) 2010; 58: 296-300.
30. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 2002; 32(Suppl): S66-81.
31. Yoo KY. Cancer control activities in the Republic of Korea. Jpn J Clin Oncol 2008; 38: 327-33.
32. Kudo M, Han KH, Kokudo N, et al. Liver Cancer Working Group report. Jpn J Clin Oncol 2010; 40(Suppl 1): i19-27.
33. Song P, Gao J, Inagaki Y, et al. Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China. Liver Cancer 2013; 2: 31-9.
34. Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011; 9: 617-23.
35. Omata M, Lesmana LA, Tateishi R, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-74.
36. Llovet JM, Di BisceglieAM, Bruix J, et al. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
37. Chua TC, Liauw W, Saxena A, et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int 2010; 30: 166-74.
38. Kim HY, Park JW, Nam BH, et al. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol 2011; 26: 1612-8.
39. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51.
40. WHO. Global Status Report on Alcohol and Health. World Health Organization. 2011. Available at http://www.who.int/substance:abuse/publications/global_alcohol_report/en/index.html. Accessed 28 March 2014.